PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/136593

Please be advised that this information was generated on 2017-04-08 and may be subject to change.
Aromatic L-Amino acid decarboxylase deficiency: A new case from Turkey with a novel mutation

Kivilcim Gucuyener¹, Cigdem Seher Kasapkara², Leyla Tumer², Marcel M. Verbeek³
¹ Department of Pediatric Neurology, Gazi University Hospital, Ankara, Turkey
² Department of Pediatric Metabolism and Nutrition, Gazi University Hospital, Ankara, Turkey
³ Department of Neurology and Laboratory Medicine, Alzheimer Center Nijmegen, Nijmegen, Netherlands

Date of Submission 31-Dec-2013
Date of Decision 12-Feb-2014
Date of Acceptance 12-Feb-2014
Date of Web Publication 17-May-2014

Correspondence Address:
Cigdem Seher Kasapkara
Department of Pediatric Metabolism and Nutrition, Gazi University Hospital, Ankara, Turkey

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0972-2327.132652

Abstract

Aromatic L-amino acid decarboxylase (AADC), a vitamin B6-requiring enzyme that converts L-dopa to dopamine and 5-hydroxytryptophan to serotonin. Deficiency of this enzyme results in developmental delay, muscular hypotonia, dystonia, involuntary movements, autonomic dysfunction, and oculogyric crises. We now report a 2-year-old Turkish boy with AADC deficiency confirmed by greatly reduced AADC activity in the plasma and by genetic studies. Mutation analysis revealed a homozygous mutation c.208C > T (p. His70Tyr) in exon 3 of the AADC gene which has not been described to date.

Keywords: Aromatic L-amino acid decarboxylase deficiency, case report, novel mutation

How to cite this article:
Gucuyener K, Kasapkara CS, Tumer L, Verbeek MM. Aromatic L-Amino acid decarboxylase deficiency: A new case from Turkey with a novel mutation. Ann Indian Acad Neurol
How to cite this URL:

Introduction

Aromatic L-amino acid decarboxylase (AADC) is a vitamin B6-requiring enzyme that converts L-dopa to dopamine and 5-hydroxytryptophan to serotonin. Deficiency of this enzyme results in developmental delay, muscular hypotonia, dystonia, involuntary movements, autonomic dysfunction, and oculogyric crises. We now report a 2-year-old Turkish boy with AADC deficiency confirmed by greatly reduced AADC activity in the plasma and by genetic studies.

Case Report

A 2-year-old male was born as the second child of healthy nonconsanguineous Turkish parents at term after an uncomplicated pregnancy and delivery. From the age of 4 months truncal muscular hypotonia, limb hypertonia, and irritability were noted by his caregivers. Physical examination showed weight loss (7.3 kg, below the third centile), length 65 cm (below the third centile), and head circumference 43 cm (below third percentile). A neurological examination revealed general hypotonia, exaggerated deep tendon reflexes with normal cranial nerve examination. He was not able to sit without assistance and did not grasp objects because of impaired eye-hand coordination. He also presented distinct extraneurological features such as hypersalivation, constipation, hyperhidrosis, and sleep disturbances. He had swallowing difficulty, recurrent vomiting and eventually evaluated for gastroesophageal reflux disease. Cranial magnetic resonance imaging, which performed because of involuntary non-epileptic dystonic movements resembling epileptic spasms, was normal. The patient had admitted several times with the complaints of dystonic movements which were interpreted as tonic epileptic movements and were given antiepileptic medications despite the existing multiple normal electroencephalography (EEG) recordings. After a careful history and reevaluation of the patient with the interpretation of the video recordings of so-called epileptic movements; patient's tonic seizure like movements were diagnosed as dystonic movements with the lateral deviation of eyes. Routine clinical investigations for inborn errors of metabolism were negative. The diagnosis of AADC deficiency was established at the age of 11 months, by screening of the cerebrospinal fluid (CSF) for neurotransmitter metabolites. Examination of a CSF sample showed a strikingly abnormal pattern of biogenic amine metabolites indicating AADC deficiency. The relevant biochemical findings were elevated concentrations of L-dopa, 3-O-methyldopa (3-OMD), and 5-hydroxytryptophan together with decreased CSF concentrations of homovanillic acid (HVA), 5-hydroxyindolacetic acid (5-HIAA), and normal levels of 5-methyltetrahydrofolate (5MTHF) and pterins [Table 1]. Diagnosis was confirmed by measurement of AADC activity
in plasma and found to be severely decreased as expected (AADC activity: <5 pmol/min/ml and normal value: 33-79). The AADC gene mutation was analyzed and sequencing results revealed a novel mutation in exon 3 of the AADC gene homozygous change c.208C > T (p. His70Tyr) which renders the patient clinical phenotype resistant to therapies. Treatment with a combination of the AADC cofactor pyridoxine and bromocriptine was started during the 1st year of life and showed only a moderate clinical improvement as decreasing the severity and duration of the dystonic episodes, but had no effect on the muscle tone and development. We added monoamine oxidase (MAO) inhibitor, melatonin, and folic acid to drug regimes; but showed no favorable response. He had not yet obtained head control or rolling over. He did not suffer from hypoglycemia, hyperprolactinemia, and growth hormone deficiency.

Table 1: The laboratory findings of the patient

<table>
<thead>
<tr>
<th><img src="https://via.placeholder.com/150" alt="Image" /></th>
<th><img src="https://via.placeholder.com/150" alt="Image" /></th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="https://via.placeholder.com/150" alt="Image" /></td>
<td><img src="https://via.placeholder.com/150" alt="Image" /></td>
</tr>
</tbody>
</table>

Discussion

Aromatic L-AADC deficiency is a rare autosomal recessive congenital metabolic disorder of neurotransmitter biosynthesis which is very intractable to treat. In general, most of the signs and symptoms with AADC deficiency can be assigned to deficiencies of dopamine, norepinephrine, epinephrine, and serotonin. In 1990, Hyland et al., diagnosed the first case of AADC deficiency by screening CSF samples in patients with psychomotor retardation. Main clinical features are muscular hypotonia, dystonia, oculogyric crises, developmental delay, and additional extraneurological symptoms. Onset of symptoms is typically in the first months of life. Although almost all patients reported so far presented oculogyric crises, current patient had not upward but lateral gaze deviation. It was difficult to discriminate seizures from nonepileptic spasms. Brain imaging and EEG revealed normal findings in most patients that are not helpful in diagnosing AADC deficiency. MRI findings that could be seen in this disorder were atrophy, reduced myelination, and white matter changes. The first step in reaching the diagnosis is the investigation of neurotransmitters in CSF. In addition to typical pattern with a distinct reduction of HVA, 5-HIAA, and 3-OMD as well as an elevation of levo-dopa and 5-hydroxytryptophan; endocrinological findings could be found, for example, elevated prolactin, hypoglycemia, and growth hormone deficiency. In general, most of the signs and symptoms described in patients with AADC deficiency can be assigned to deficiencies of dopamine, norepinephrine, epinephrine, and serotonin. Drug therapy aims at correcting the central and peripheral deficiency of serotonin and catecholamines. Medical treatment is challenging and first choice medications appear to be dopamine agonists in combination with pyridoxine and MAO inhibitors, anticholinergics, melatonin, and others are thought in the second step. While some children have demonstrated some benefit, the overall outcome is unsatisfactory. He was started on pyridoxine, pyridoxal phosphate, folic acid, MAO inhibitor, and trihexyphenidyl; but without any clinical improvement. He was extremely hypotonic, with no head control and never achieved verbal output and any developmental milestones. As far as we now, the mutation that was found in this patient has not been described earlier and unfortunately, the response to treatment was very poor. Cerebrospinal fluid neurotransmitter metabolite profile remains a critical tool in identifying patients with suspected neurotransmitter deficiency state. Treatment options are limited, in many cases not beneficial, and prognosis is uncertain. In the literature, the majority of cases showed no or poor response despite different protocols and a combination of different drugs.
From the clinical point of view in order to diagnose those patients as early and correctly as possible, a thorough evaluation in terms of medical history and physical and neurological examination should be done in order to rule out epileptic disorders. For now, we expect the development of new strategies and more effective treatments.

References


